Compare Eli Lilly And Co (LLY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tilray Brands Inc — how do they compare? Eli Lilly And Co trades at $1,159.28 (market cap $1.02T), while Tilray Brands Inc trades at $4.25 (market cap $524.07M). The key difference: Eli Lilly And Co is far larger — about 1946.3× Tilray Brands Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| LLY | TLRY | |
|---|---|---|
Market Cap | $1.02T | $524.07M |
Sector | Health | Health |
52-Week High | $1.24K | $21.00 |
52-Week Low | $625.65 | $4.23 |
Enterprise Value | $1.06T | $621.22M |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $4.23, down 1.63% with bearish technical signals. The company reported revenue growth to $821.31M in 2025 but faces severe profitability challenges with a net loss of $2.19B and negative margins. Recent expansion includes medical cannabis launches in Panama and strategic acquisitions, while analyst consensus shows cautious sentiment with 65% hold ratings.
The outlook remains challenging due to persistent losses and high debt levels, though expansion initiatives and potential regulatory changes offer long-term opportunities. Key risks include execution on profitability, competitive pressures, and cannabis regulatory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
